CBD Life Sciences Inc. Expands Global Footprint With Strategic Manufacturing Deal and Product Innovation

CBD Life Sciences Inc. expands global manufacturing reach with a major Colombian partnership and launches a premium full-spectrum CBD gummy, driving growth in the expanding wellness market.

CBD Life Sciences Inc. (OTC: CBDL) is accelerating its growth trajectory with major strategic initiatives that strengthen its global manufacturing capacity and product portfolio in the rapidly expanding cannabidiol (CBD) wellness market.

In a key milestone for 2025, CBD Life Sciences announced a new manufacturing agreement with Thallos, a Colombian firm, aimed at producing high-potency CBD formulations exclusively under Thallos’ brand. This collaboration positions CBDL as a central manufacturing partner in a Latin American market projected to exceed $4.9 billion by 2028, underscoring the company’s commitment to international expansion and diversified revenue streams. Under the agreement, CBDL will oversee production, packaging, and quality assurance of flagship products including 2,000 mg CBD salves and tinctures — leveraging its in-house facilities to ensure stringent standards and operational efficiency.

Alongside manufacturing growth, CBD Life Sciences has also unveiled a 100 mg full-spectrum CBD gummy designed to support mental focus and daily well-being. This premium newcomer, available in Crisp Green Apple and Wild Blueberry flavors, reflects CBDL’s strategic push into niche wellness categories with functional formulations aimed at stress management and cognitive support — key segments within the broader CBD and holistic health industry.

CEO Lisa Nelson emphasized the company’s mission to innovate while staying attuned to evolving consumer needs, blending quality cannabinoids with targeted product positioning to meet rising demand. These efforts coincide with CBD Life Sciences’ broader expansion strategy, which includes entering high-growth retail markets and cultivating partnerships across the U.S. and abroad.

With the global CBD marketplace forecasted to grow steadily through the decade, CBD Life Sciences Inc. continues to fortify its manufacturing capabilities and enhance its product lineup, aiming to secure a competitive edge in an increasingly crowded wellness landscape.